

Completion if Known

Application Number	NYA
Filing Date	June 26, 2003
First Named Inventor	JERDAN
Art Unit	NYA
Examiner Name	NYA
Attorney Docket Number	2422 US

(Use as many sheets as necessary)

Sheet 1 of 2

[illegible][illegible]

Examiner Signature	Zohrab Fay	Date Considered	9/22/04
-----------------------	------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	NYA
Filing Date	June 26, 2003
First Named Inventor	JERDAN
Art Unit	NYA
Examiner Name	NYA
Attorney Docket Number	2422 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2.F	B1	Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal..., Arch, Ophthalmol., 1999, Vol. 117:1329-45.	
2.F	B2	The EyeTech Study Group. Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF pegylated aptamer (EYE001) for the treatment..., Retina, 2002, Vol. 22:142-52.	
2.F	B3	KRZYSTOLIK, et al., Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment, Arch, Ophthalmol., 2002, Vol. 120:338-46.	
2.F	B4	DEFALLER, et al., A new pharmacological treatment for angiogenesis. In Pterygium, Taylor, HR (ED.) The Hague: Kugler Publications, 2000, 169-181.	
2.F	B5	PENN, et al., The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity, Invest. Ophthalmol. Vis. Science, 2001, Vol. 42:283-90.	
2.F	B6	CASEY, et al., Factors Controlling Ocular Angiogenesis, Amer. J. Ophthalmol., 1997, Vol. 124: 521-529.	
2.F	B7	CLARK, A.F., AL-3789: a novel ophthalmic angiostatic steroid, Exp. Opin. Invest. Drugs, 1997, Vol. 6:1867-77.	
2.F	B8	MCNATT, et al., Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization, J. Ocular Pharm. Therap., 1999, Vol. 15(5):413-23.	
2.F	B9	BENEZRA, et al., Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization, Invest. Ophthalmol. Vis. Science, 1997, Vol. 38:1954-62.	
2.F	B10		

Examiner Signature

Zohreh Fay

Date Considered

9/22/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.